Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models

  • Jiménez de Oya, Nereida
  • Esler, William P.
  • Huard, Kim
  • El-Kattan, Ayman F.
  • Karamanlidis, Georgios
  • Blázquez, Ana B.
  • Ramos-Ibeas, Priscila
  • Escribano-Romero, Estela
  • Louloudes-Lázaro, Andrés
  • Casas, Josefina
  • Sobrino Castelló, Francisco
  • Hoehn, Kyle
  • James, David E.
  • Gutiérrez-Adán, Alfonso
  • Saiz Calahorra, Juan Carlos
  • Martín-Acebes, M. A.
Flaviviruses are (re)-emerging RNA viruses strictly dependent on lipid metabolism for infection. In the search for host targeting antivirals, we explored the effect of pharmacological modulation of fatty acid metabolism during flavivirus infection. Considering the central role of acetyl-Coenzyme A carboxylase (ACC) on fatty acid metabolism, we analyzed the effect of three small-molecule ACC inhibitors (PF-05175157, PF-05206574, and PF-06256254) on the infection of medically relevant flaviviruses, namely West Nile virus (WNV), dengue virus, and Zika virus. Treatment with these compounds inhibited the multiplication of the three viruses in cultured cells. PF-05175157 induced a reduction of the viral load in serum and kidney in WNV-infected mice, unveiling its therapeutic potential for the treatment of chronic kidney disease associated with persistent WNV infection. This study constitutes a proof of concept of the reliability of ACC inhibitors to become viable antiviral candidates. These results support the repositioning of metabolic inhibitors as broad-spectrum antivirals., This work was supported by Spanish Ministry of Economy and Competitiveness (MINECO) Fondo Europeo de Desarrollo Regional (FEDER) under Grant AGL2014-56518-JIN to M.A.M-A; INIA under Grant RTA2015-009 to J.-C.S.; and the Comunidad Autónoma de Madrid under Grant P2013/ABI-2906 (PLATESA) to J.-C.S and F.S. We thank the Pfizer Compound Transfer Program (Grants WI215864 and WI201531 to M.A.M.-A.) for providing the ACC inhibitors for cell culture and in vivo assays., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clinical infections by herpesviruses in patients treated with valproic acid: a nested case-control study in the spanish primary care database, BIFAP

  • Gil, Miguel
  • González-González, Rocío
  • Vázquez-Calvo, Ángela
  • Álvarez-Gutiérrez, Arturo
  • Martín-Acebes, M. A.
  • Praena, Beatriz
  • Bello-Morales, Raquel
  • Saiz Calahorra, Juan Carlos
  • López-Guerrero, José Antonio
  • Tabarés, Enrique
  • Sobrino Castelló, Francisco
The objective of this study is to evaluate the risk of clinical infections by herpesviruses in patients exposed to valproic acid (VPA). We performed a case-control study nested in a primary cohort selected from the Spanish primary care population-based research database BIFAP (Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria) over the period 2001–2015. The events of interest were those diseases caused by any herpesviruses known to infect humans. For each case, up to 10 controls per case matched by age, gender, and calendar date were randomly selected. A conditional logistic regression was used to compute adjusted odds ratios (OR) and their 95% confidence intervals (95% CI). Current use of VPA was associated with a trend towards a reduced risk of clinical infections by herpesviruses as compared with non-users (OR 0.84; CI 95% 0.7–1.0; p = 0.057). Among current users, a trend to a decreased risk with treatment durations longer than 90 days was also observed. The results show a trend to a reduced risk of clinical infection by herpesviruses in patients exposed to VPA. These results are consistent with those in vitro studies showing that, in cultured cells, VPA can inhibit the production of the infectious progeny of herpesviruses. This study also shows the efficient use of electronic healthcare records for clinical exploratory research studies., Work at Centro de Biología Molecular Severo Ochoa was supported by grants from the Spanish Ministerio de Economía y Competitividad (AGL2014-52395-C2-1-R and AGL2017-84097-C2-1-R), and by an institutional grant from the Fundación Ramón Areces and Banco Santander Central Hispano. Work at INIA (MAM-A) was supported by grant AGL2014-56518-JIN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipid Metabolism as a Source of Druggable Targets for Antiviral Discovery against Zika and Other Flaviviruses

  • Martín-Acebes, M. A.
  • Jiménez de Oya, Nereida
  • Saiz Calahorra, Juan Carlos
11 Pág., The Zika virus (ZIKV) is a mosquito-borne flavivirus that can lead to birth defects (microcephaly), ocular lesions and neurological disorders (Guillain-Barré syndrome). There is no licensed vaccine or antiviral treatment against ZIKV infection. The effort to understand the complex interactions of ZIKV with cellular networks contributes to the identification of novel host-directed antiviral (HDA) candidates. Among the cellular pathways involved in infection, lipid metabolism gains attention. In ZIKV-infected cells lipid metabolism attributed to intracellular membrane remodeling, virion morphogenesis, autophagy modulation, innate immunity and inflammation. The key roles played by the cellular structures associated with lipid metabolism, such as peroxisomes and lipid droplets, are starting to be deciphered. Consequently, there is a wide variety of lipid-related antiviral strategies that are currently under consideration, which include an inhibition of sterol regulatory element-binding proteins (SREBP), the activation of adenosine-monophosphate activated kinase (AMPK), an inhibition of acetyl-Coenzyme A carboxylase (ACC), interference with sphingolipid metabolism, blockage of intracellular cholesterol trafficking, or a treatment with cholesterol derivatives. Remarkably, most of the HDAs identified in these studies are also effective against flaviviruses other than ZIKV (West Nile virus and dengue virus), supporting their broad-spectrum effect. Considering that lipid metabolism is one of the main cellular pathways suitable for pharmacological intervention, the idea of repositioning drugs targeting lipid metabolism as antiviral candidates is gaining force., This research was funded by The Spanish Ministry of Economy and Competitiveness, grant number AGL2014-56518-JIN (to M.A.M-A.), Peer reviewed